- Home
- PETZ vs IBIO Comparison
PETZ vs IBIO Comparison
Compare PETZ & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETZ
- IBIO
- Stock Information
- Founded
- PETZ 2002
- IBIO 2008
- Country
- PETZ China
- IBIO United States
- Employees
- PETZ N/A
- IBIO N/A
- Industry
- PETZ Steel/Iron Ore
- IBIO Biotechnology: Pharmaceutical Preparations
- Sector
- PETZ Industrials
- IBIO Health Care
- Exchange
- PETZ Nasdaq
- IBIO Nasdaq
- Market Cap
- PETZ 10.3M
- IBIO 9.3M
- IPO Year
- PETZ 2017
- IBIO N/A
- Fundamental
- Price
- PETZ $0.95
- IBIO $0.77
- Analyst Decision
- PETZ
- IBIO Strong Buy
- Analyst Count
- PETZ 0
- IBIO 3
- Target Price
- PETZ N/A
- IBIO $4.87
- AVG Volume (30 Days)
- PETZ 11.7K
- IBIO 776.1K
- Earning Date
- PETZ 04-28-2025
- IBIO 05-02-2025
- Dividend Yield
- PETZ N/A
- IBIO N/A
- EPS Growth
- PETZ N/A
- IBIO N/A
- EPS
- PETZ 0.26
- IBIO N/A
- Revenue
- PETZ $563,726.00
- IBIO $375,000.00
- Revenue This Year
- PETZ N/A
- IBIO $36.00
- Revenue Next Year
- PETZ N/A
- IBIO N/A
- P/E Ratio
- PETZ $4.65
- IBIO N/A
- Revenue Growth
- PETZ 74664.72
- IBIO 650.00
- 52 Week Low
- PETZ $0.65
- IBIO $0.64
- 52 Week High
- PETZ $1.74
- IBIO $6.89
- Technical
- Relative Strength Index (RSI)
- PETZ 47.17
- IBIO 30.08
- Support Level
- PETZ $0.86
- IBIO $0.70
- Resistance Level
- PETZ $0.96
- IBIO $0.83
- Average True Range (ATR)
- PETZ 0.07
- IBIO 0.06
- MACD
- PETZ 0.01
- IBIO 0.08
- Stochastic Oscillator
- PETZ 75.39
- IBIO 41.18
About PETZ TDH Holdings Inc.
TDH Holdings Inc is engaged in the business of manufacturing and selling of petfood and restaurant operations. The company has two operating segments which include Petfood sales and Restaurant business. It has a focus on the Restaurant business segment and generates the majority of its revenue.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.